Estrone Is a Clue

Companion to Episode 7 · Part of HRT for Women Throughout Life

Before you read: This guide is here to help you understand your own hormone care and ask better questions, not to replace your doctor, and not so you can adjust anything on your own. Read it, and bring it with you to your appointment.

The moment this paper is for

Labs now arrive before the appointment. That is a good change, and it has a cost. A woman opens her report, sees a line called estrone, and finds that nobody has ever explained it to her. She searches the word. Within two clicks she is reading about cancer.

The number was delivered without context, so it arrives as a verdict instead of as a piece of data. From there the outcomes tend to go one of two ways. Some women stop therapy immediately and tell no one. Others stay on therapy and stop trusting it. Both of those outcomes were produced by an uninterpreted lab value, not by a hormone.

Estrone in one paragraph

You have three estrogens: estradiol, estriol, and estrone. Estradiol is the one most hormone therapy is built around, because it binds estrogen receptors well and does the work women are usually looking for, including relief of hot flashes and night sweats, and support of bone. From your first period until menopause, estradiol is the dominant estrogen. After menopause, estrone becomes the dominant one.

That shift is worth sitting with. Estrone is not an intruder in the postmenopausal body. It is what the body still has.

What estrone does well, and where it falls short

At ordinary levels, estrone is not idle. It contributes to bone and to lipid handling, and it partly fills the space estradiol used to fill. Calling it useless has never been accurate.

It is also not a full substitute. It does not manage hot flashes and night sweats the way estradiol does. A woman running on estrone alone is not being covered for the symptoms that brought her in.

Where the fear came from, and what it actually says

The concerning research on estrone is real, and it deserves to be described accurately rather than either dismissed or inflated.

It centers on estrone in an inflamed body. When inflammatory signaling is high, particularly in fat tissue, laboratory research describes estrone participating in pathways that can push toward insulin resistance and further inflammation. Those studies are largely mechanistic, meaning they are done in cells and animal models rather than in long-term human outcome trials. Mechanistic work is a legitimate reason for care and monitoring. It is not the same thing as an outcome you can promise a woman.

The failure in how this has been communicated is that the claim outran the evidence. "Estrone" became shorthand for cancer, diabetes, and obesity, and the nuance disappeared.

There is also a question of order that rarely gets asked. In an inflamed, insulin-resistant body, fat tissue makes more estrone, and that estrone can feed back into the same inflammatory environment. So which came first? The honest answer in most cases is that the inflammation was already there. Estrone is often reporting the fire, not starting it.

The correction that matters most

For years, in this field broadly and in teaching from clinicians who meant to protect women, estrone was described simply as the bad estrogen. That shorthand was well-intentioned and it caused harm. It turned a lab value into a hurdle.

Estrone levels have become a gatekeeper. Women have been denied hormone therapy, or told to stop it, on the strength of one line on a report.

That is the wrong use of the number. An estrone value does not change whether a woman is deficient in estradiol, and deficiency is what replacement addresses. Estrone belongs in the conversation about route, monitoring, and metabolic health. It does not belong in the decision about whether a woman is permitted to have her hormones replaced at all.

What a clinician should actually do with an elevated estrone

There are two branches, and both of them end in continued care.

If you take estrogen by mouth. Anything swallowed passes through the liver first, and a large share of oral estradiol is converted to estrone on the way. An elevated estrone in a woman on oral estrogen is usually reporting the route. A marker of inflammation called C-reactive protein often rises alongside it, and in this setting that rise reflects the liver's response to oral hormone rather than being a clean read on blood vessel health. Seeing both elevated together is a recognizable pattern. It is a reason to discuss route and overall risk. It is not a reason to withhold estrogen.

If you take estrogen by another route, such as a patch, an injection, or an implant, and estrone is still elevated, the question moves to metabolism. Fasting insulin, a broader panel of inflammatory markers, and where weight is carried, particularly around the abdomen, all become relevant. Here again, an elevated estrone does not mean a woman should not receive estrogen. It means she is owed a metabolic conversation, and a plan aimed at reducing inflammation.

This is achievable work. It is slower than changing a prescription and it is more useful.

A word about what gets sold to you

When estrone becomes frightening, products follow. Something will be marketed to you to lower your estrone, clear your estrogen, or protect you.

Here is the distinction worth carrying. If someone tells you your estrone is elevated and their answer is their branded product line, that is a sale. If someone tells you your estrone is elevated, explains what they think is driving it, describes a strategy aimed at that driver, and then tells you how they will show you the result in your own labs, that is a clinical conversation. The tell is measurement. A plan that cannot be checked is a promise, not a treatment.

Endocrine-disrupting compounds

Compounds including BPA and phthalates are known to interact with hormone signaling, and there is emerging work suggesting they can influence how the body handles its own steroid hormones, including patterns that may show up as higher estrone.

This research is not settled, and it should not be presented as if it were. It is offered here because you deserve to know what is being studied and where the uncertainty sits, not because it should change what you do this week. Reducing plastic exposure in food and drink is reasonable and low-risk regardless of how this literature resolves. It is not a substitute for the metabolic work described above.

Key terms

• Estrone. One of three estrogens; the dominant one after menopause.
• First pass. The liver's initial handling of anything swallowed, which converts much oral estradiol into estrone.
• Aromatase. The enzyme, active in fat tissue, that produces estrone from other hormones.
• Mechanistic research. Laboratory work describing how something could happen, distinct from trials measuring what happens to people over time.

Questions worth bringing to your appointment

• Why was my route chosen, and does estrone play a part in that reasoning?
• What does my estrone suggest alongside my other labs, particularly my insulin and inflammatory markers?
• If we want to change this number, how will we know whether it worked?
• What would make us change the plan, and what would make us leave it alone?

Please read this before you act on anything above

Do not start, stop, increase, decrease, or otherwise adjust hormone therapy because of a single lab value, including an estrone value, and including anything in this paper. An estrone result is a conversation with a qualified clinician. It is not a verdict from a search bar.